Business News • PR NewsWire • OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

STOCKHOLM, Sweden, Aug. 23, 2019 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that, based on a positive opinion from the Paediatric Committee (PDCO), the EMA has agreed to...

View More : https://www.prnewswire.com:443/news-releases/oxthera-receives-positive-decision-from-ema-on-paediatric-investigational-p...

Releted News by prnewswire

AlzeCure Publishes its Interim Report for January - June 2019

Nearly 20,000 Dancers Gather at Kochi "Yosakoi Festival," Many from U.S., Europe and Asia

FLNG Market Annual Production to Hit 300 Metric Ton by 2024: Global Market Insights, Inc.

Arcadia Biosciences Announces Management Succession; Provides Financial Guidance

Arcadia Biosciences Enters Global Collaboration with Arista Cereal Technologies and Bay State Milling Company for Commercialization of High Fiber Wheat